Oncologists treating ROS1-positive advanced non–small cell lung cancer (NSCLC) are increasingly focusing on precision sequencing after first-line tyrosine kinase inhibitor (TKI) failure. According to Bruna Pellini, MD, chief of Thoracic Medical Oncology at Baptist Health Herbert Wertheim Cancer Institute, the choice of second-line therapy is now driven by resistance mechanisms like the G2032R mutation, intracranial disease control, and emerging data on next-generation inhibitors like taletrectinib and repotrectinib.
How does resistance impact second-line treatment choices?
When a patient progresses on a first-line TKI such as entrectinib, the specific mechanism of resistance dictates the next clinical move. Data presented by Dr. Pellini at a virtual Case-Based Roundtable highlighted that the ROS1 G2032R mutation—a solvent-front substitution—is a primary driver of resistance. Molecular profiling via tissue or plasma biopsy at the time of progression is now considered a standard requirement to determine if a patient remains a candidate for targeted agents or requires a clinical trial.
How do taletrectinib and repotrectinib compare in the pretreated setting?
Clinical data shows distinct differences in efficacy, particularly regarding intracranial response. According to the TRUST I and TRUST II trials, taletrectinib demonstrated an intracranial confirmed objective response rate (ORR) of up to 75.0% in specific cohorts. In comparison, the TRIDENT-1 trial reported an intracranial ORR of 38% for repotrectinib.
| Agent | Intracranial ORR | Key Data Source |
|---|---|---|
| Taletrectinib | 56.3% – 75.0% | TRUST I & II |
| Repotrectinib | 38% | TRIDENT-1 |
While taletrectinib showed an 80% ORR in a small subset of 10 entrectinib-pretreated patients, Dr. Pellini noted that durability remains an open question. Median progression-free survival (PFS) in the TRUST II study reached 11.8 months, though researchers caution that shorter follow-up periods compared to earlier trials necessitate a nuanced interpretation of these figures.
What role does zidesamtinib play in the future of ROS1 care?
For patients who have exhausted standard targeted therapies, zidesamtinib (NVL-520) is emerging as a critical investigational option. Early data from the ARROS-1 study indicates an ORR near 44% in heavily pretreated patients. This macrocyclic ROS1 inhibitor is designed to address the G2032R resistance mutation, offering a potential path for patients who no longer respond to first- or second-generation TKIs.
Frequently Asked Questions
Is molecular profiling necessary at every progression?
Yes. According to Dr. Pellini, identifying specific resistance mutations like G2032R is essential to determine whether a patient should switch to a different TKI, enroll in a clinical trial, or consider off-label combinations.
What is the standard of care after entrectinib failure?
There is no single standard, but clinical preference in the roundtable leaned heavily toward taletrectinib (71%) and repotrectinib (21%) due to their efficacy against known resistance mutations and activity in the central nervous system.
Can chemotherapy be combined with a TKI?
Some clinicians use platinum-based chemotherapy alongside a TKI, but this approach is often hindered by insurance coverage challenges.
Are you managing patients with ROS1-positive NSCLC? Explore our resource library for more updates on clinical trials and targeted therapy sequencing.
